Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic

The phosphatidylinositol-3-kinase (PI3K) pathway is ubiquitous to multiple cellular processes and is intricately implicated in lymphomagenesis. The development of PI3K inhibitors has broadened treatment options for relapsed and/or refractory follicular lymphoma (FL) and currently three PI3K inhibitors have been approved in the third-line setting for FL, including idelalisib (oral), duvelisib (oral), and copanlisib (intravenous), with other agents under investigation. In this review, we discuss the clinical advance of copanlisib through preclinical to Phase III trials, its unique cellular targets and side effect profile that have poised it as a safer and equally efficacious option when compared to the oldergeneration oral PI3Kis, and its utility to the clinician as part of the therapeutic armamentarium for relapsed and/or refractory FL.

Automated summary

The development of PI3K inhibitors has expanded treatment options for follicular lymphoma (FL), with copanlisib emerging as a safer and equally effective choice compared to older generation oral PI3Kis, making it an important drug for clinicians in the therapeutic armamentarium for treating FL.